Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects
Public ClinicalTrials.gov record NCT04451954. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens Without or With Adjuvant in Healthy Adult Subjects
Study identification
- NCT ID
- NCT04451954
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Interventions
- Quadrivalent RIV with 2018-2019 NH H3 strain Biological
- Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant Biological
- Quadrivalent RIV with H3 strain 1 Biological
- Quadrivalent RIV with H3 strain 1 and adjuvant Biological
- Quadrivalent RIV with H3 strain 2 Biological
- Quadrivalent RIV with H3 strain 2 and adjuvant Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1, 2020
- Primary completion
- Sep 19, 2021
- Completion
- Sep 19, 2021
- Last update posted
- Sep 16, 2025
2020 – 2021
United States locations
- U.S. sites
- 5
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 8400003 | San Diego | California | 92108 | — |
| Investigational Site Number 8400002 | Melbourne | Florida | 32934 | — |
| Investigational Site Number 8400004 | Orlando | Florida | 32806 | — |
| Investigational Site Number 8400001 | Peoria | Illinois | 61614 | — |
| Investigational Site Number 8400005 | Rockville | Maryland | 20850 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04451954, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04451954 live on ClinicalTrials.gov.